Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 2,366 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 2,366 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $92.25, for a total value of $218,263.50. Following the transaction, the chief executive officer now owns 136,215 shares in the company, valued at approximately $12,565,833.75. This trade represents a 1.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Grant Pickering also recently made the following trade(s):

• On Monday, December 2nd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $92.45, for a total value of $1,386,750.00.
• On Thursday, November 7th, Grant Pickering sold 2,366 shares of Vaxcyte stock. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74.
• On Friday, November 1st, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $106.82, for a total transaction of $1,602,300.00.
• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The stock was sold at an average price of $109.21, for a total transaction of $775,172.58.

Vaxcyte Trading Up 0.7 %

PCVX opened at $91.05 on Thursday. The company has a market cap of $11.35 billion, a P/E ratio of -19.79 and a beta of 0.94. The company’s 50 day moving average is $102.51 and its 200-day moving average is $91.41. Vaxcyte, Inc. has a 1-year low of $53.83 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the firm posted ($0.91) EPS. On average, equities analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. grew its holdings in shares of Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock worth $315,162,000 after purchasing an additional 324,560 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in Vaxcyte during the 3rd quarter worth approximately $507,000. Virtu Financial LLC bought a new stake in Vaxcyte during the 3rd quarter worth approximately $355,000. Geode Capital Management LLC raised its stake in shares of Vaxcyte by 10.6% during the third quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock valued at $308,675,000 after acquiring an additional 259,010 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. acquired a new position in shares of Vaxcyte during the third quarter worth $92,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PCVX shares. Jefferies Financial Group increased their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Leerink Partners increased their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. Finally, Mizuho boosted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.